vTv Therapeutics Inc to Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 Conference Call

10/2/2020 8:30

Conference Call vTv Therapeutics Inc

vTv Therapeutics Inc Conference call will be held on Feb 10, 2020. During the earnings conference call's session vTv Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact vTv Therapeutics Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. We have a powerful pipeline of clinical drug candidates, led by our programs for the treatment of Alzheimer's disease ("AD") and type 2 diabetes. Our drug candidate for the treatment of AD, azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts ("RAGE"), for which we have commenced patient enrollment and have successfully completed the enrollment of sub-study A in a Phase 3 clinical trial (the "STEADFAST Study") under a Food and Drug Administration ("FDA") agreed Special Protocol Assessment ("SPA").
Read more Conference Call

vTv Therapeutics Inc (VTVT)

4170 Mendenhall Oaks Parkway, High Point North Carolina 27265, United States